Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene

Gene Therapy

Volumn 3, Issue 7, 1996, Pages 567-580

  Raben, D ^a   Buchsbaum, D J ^a   Khazaeli, M B ^b   Rosenfeld, M E ^a   Gillespie, G Y ^c   Grizzle, W E ^d   Liu, T ^b   Curiel, D T ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adenovirus; Antibody binding; Antibody localization; Carcinoembryonic antigen; Gene therapy; Gene transfer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; COMPLEMENTARY DNA; IODINE 125; IODINE 131; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; RADIOLIGAND;

ADENOVIRUS; ANTIGEN BINDING; ARTICLE; COLON CANCER; EXPRESSION VECTOR; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RADIOIMMUNOTHERAPY; REPORTER GENE; TARGET CELL; TUMOR LOCALIZATION; VIRUS RECOMBINANT;

ADENOVIRUSES, HUMAN; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; GENETIC VECTORS; GLIOMA; HUMANS; IODINE RADIOISOTOPES; TRANSFECTION; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; CYTOMEGALOVIRUS;

EID: 0029782168     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. 131I] anti-B1 (anti-CD20) antibody. New Engl J Med 1993; 329: 459-165.
2. Press OW et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. New Engl J Med 1993; 329: 1219-1224.
3. Goldenberg DM, Blumenthal RD, Sharkey RM. Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies. Semin Radiat Oncol 1990; 1: 217-225.
4. Blumenthal RD et al. Physiological factors influencing radioantibody uptake: a study of four human colonic carcinomas, Int J Cancer 1992; 52: 1-7.
5. Buchsbaum DJ, Langmuir VK, Wessels BW. Experimental radioimmunotherapy. Med Phys 1993; 20: 551-567.
6. Buchsbaum DJ. Experimental radioimmunotherapy and methods to increase therapeutic efficacy. In: Goldenberg DM (ed). Cancer Therapy with Radiolabeled Antibodies. CRC Press: Boca Raton, 1995, pp 115-140.
7. Becker TC et al Use of recombinant adenovirus for metabolic engineering of mammalian cells. Meth Cell Biol 1994; 43: 161-189.
8. Goldenberg DM et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. New Engl J Med 1978; 298: 1384-1388.
9. 90Y-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 1988; 48: 3270-3275.
10. Bischof-Delaloye A et al. Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study. J Nucl Med 1989; 30: 1646-1656.
11. 2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med 1990; 31: 1035-1044.
12. Sharkey RM et al. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res 1990; 50: 2330-2336.
13. 90Y-α-caranoembryonic antigen monoclonal antibody. Cancer Res 1991; 51: 3802-3806.
14. Goldenberg DM Imaging and therapy of gastrointestinal cancers with radiolabeled antibodies. Am J Gastroenterol 1991; 86: 1392-1403.
15. Corbisiero RM et al. Comparison of immunoscintigraphy and computerized tomography in identifying colorectal cancer: individual lesion analysis. Cancer Res 1991; 51: 5704-5711.
16. Goldenberg DM, Larson SM. Radioimmunodetection in cancer identification. J Nucl Med 1992; 33: 803-814.
17. 131I-labeled monoclonal antibodies. Cancer Res 1992; 52: 6036-6044.
18. Goldenberg DM et al. Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. J Nucl Med 1993; 34: 61-70.
19. Sharkey RM et al. Clinical evaluation of tumor targeting with a high-affinity anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 1993; 71: 2082-2096.
20. Blumenthal RD et al. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res 1994; 54: 142-151.
21. 2 in colorectal cancer patients. Cancer 1994; 73: 850-857.
22. Behr TM et al. Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med 1995; 36: 430-441.
23. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439-462.
24. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991; 5: 344-366.
25. Hefta LJF et al. Expression of complementary DNA and genomic clones for carcinoembryonic antigen and nonspecific crossreacting antigen in Chinese hamster ovary and mouse fibroblast cells and characterization of the membrane-expressed products. Cancer Res 1990; 50: 2397-2403.
26. Robbins FF et al. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 1991; 51: 3657-3662.
27. Hand PH et al. Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies. Cancer Immunol Immunother 1993; 36: 65-75.
28. Guadagni F et al. Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon. Cancer Immunol Immunother 1988; 26: 222-230.
29. 111In-labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 1988; 80: 160-165.
30. Kuhn JA et al. Interferon enhancement of radioimmunotherapy for colon carcinoma. Cancer Res 1991; 51: 2335-2339.
31. Greiner JW et al. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol 1992; 10: 735-746.
32. 131I-CC49) when given in combination with γ-interferon. Cancer Res 1993, 53: 600-608.
33. Aaronson SA. Growth factors and cancer. Science 1991; 254: 1146-1153.
34. De Santes K et al. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992: 52: 1916-1923.
35. Larson S Receptors on tumors studied with radionuclide scintigraphy. J Nucl Med 1991; 32: 1189-1191
36. Krenning EP et al. Somatostatin receptor scintigraphy. Nucl Med Ann 1995; XI: 1-50.
37. Virgolini I et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. New Engl J Med 1994; 331: 1116-1121.
38. Weichselbaum RR, Hallahn DE, Sukhatme VP. Kufe DW. Gene therapy targeted by ionizing radiation, Int J Radiat Oncol Biol Phys 1992; 24: 565-567.
39. Kim JH, Kim SH, Brown SL, Freytag SO. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res 1994; 54: 6053-6056.
40. Garver RI Jr et al. Strategy for achieving selective killing of carcinomas. Gene Therapy 1994; 1: 46-50.
41. DiMaio JM et al. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994; 116: 205-213.
42. Osaki T el al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 1994; 54: 5258-5261.
43. Manome Y et al. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res 1994; 54: 5408-5413.
44. Vile RG et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
45. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 1995; 6: 881-893.
46. Gazit G, Kane SE, Nichols P, Lee AS. Use of the stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrosarcoma in vivo. Cancer Res 1995; 55: 1660-1663.
47. Giard DJ et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973; 51: 1417-1423.
48. Bigner SH et al. Relationship of in vitro morphologic and growth characteristics of established human glioma-derived cell lines to their tumorigenicity in athymic nude mice. J Neuropathol Exp Neurol 1981; 40: 390-409.
49. Goldman CK et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993; 4: 121-133.
50. 131I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts Int J Radiat Oncol Biol Phys 1990; 18: 1033-1041.
51. Buchsbaum D et al. Localization and imaging of radiolabeled monoclonal antibodies against colorectal carcinoma in tumor-bearing nude mice. Cancer Res 1988; 48: 4324-4333.
52. Guadagni F et al. Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-γ. Cancer Res 1990; 50: 6248-6255.
53. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993; 90: 2812-2816.
54. Feng M et al. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res 1995; 55: 2024-2028.
55. Muraro R et al. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res 1985; 45: 5769-5780.
56. Muraro R et al. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res 1988; 48: 4588-4596.
57. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1, 3, 4, 6-tetrachloro-3α, 6α-diphenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849-857.
58. 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts. Int J Radiat Oncol Biol Phys 1993; 25: 629-638.
59. Lindmo T et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Meth 1984; 72: 77-89.
60. 131I-labeled monoclonal antibody CC49. Cancer Res 1995; 55: 5881s-5887s.
61. Meredith RF et al. Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer. Hum Antibod Hybrid 1993; 4: 190-197.
62. Myers RB et al. Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. J Urol 1994; 152: 243-246.
63. Myers RB, Srivastava S, Grizzle WE. Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma. J Urol 1995; 153: 1572-1574.
64. Snedecor GW, Cochran WG. Statistical Methods. 7th edn. The Iowa State University Press: Ames, IA, 1980.